This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n19http://localhost/temp/predkladatel/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n14http://linked.opendata.cz/resource/domain/vavai/subjekt/
n13http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n7http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F14%3A43908087%21RIV14-MSM-11120___/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n11http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F14%3A43908087%21RIV14-MSM-11120___
rdf:type
skos:Concept n13:Vysledek
dcterms:description
Guidelines recommend beta-blockers and renin-angiotensin-aldosterone system blockers to improve long-term survival in hemodynamically stable myocardial infarction patients with a reduced left ventricular ejection fraction. The prevalence and outcomes associated with beta and renin-angiotensin-aldosterone system blocker therapy in patients with ongoing cardiogenic shock is unknown. In patients with cardiogenic shock lasting more than 24 hours enrolled in Tilarginine Acetate Injection in a Randomized International Study in Unstable Myocardial Infarction Patients With Cardiogenic Shock, we compared 30-day mortality in patients who received beta or renin-angiotensin-aldosterone system blockers within 24 hours of randomization with those who did not. The final study population included 240 patients. A total of 66 patients (27.5%) had either beta blocker or renin-angiotensin-aldosterone system blocker administered within the first 24 hours after the diagnosis of cardiogenic shock. Beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aldosterone antagonists were prescribed in 18.8%, 10.6%, and 5.0% of patients, respectively. The observed 30-day mortality among patients was higher in patients who received beta or renin-angiotensin-aldosterone system blockers prior to cardiogenic shock resolution. Compared with patients not given beta or renin-angiotensin-aldosterone system blockers, the 30-day mortality was higher among patients treated only with beta-blockers but not among those only treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The administration of beta or renin-angiotensin-aldosterone system blockers is common in North America and Europe in patients with myocardial infarction and cardiogenic shock prior to cardiogenic shock resolution. This therapeutic practice was independently associated with higher 30-day mortality. Guidelines recommend beta-blockers and renin-angiotensin-aldosterone system blockers to improve long-term survival in hemodynamically stable myocardial infarction patients with a reduced left ventricular ejection fraction. The prevalence and outcomes associated with beta and renin-angiotensin-aldosterone system blocker therapy in patients with ongoing cardiogenic shock is unknown. In patients with cardiogenic shock lasting more than 24 hours enrolled in Tilarginine Acetate Injection in a Randomized International Study in Unstable Myocardial Infarction Patients With Cardiogenic Shock, we compared 30-day mortality in patients who received beta or renin-angiotensin-aldosterone system blockers within 24 hours of randomization with those who did not. The final study population included 240 patients. A total of 66 patients (27.5%) had either beta blocker or renin-angiotensin-aldosterone system blocker administered within the first 24 hours after the diagnosis of cardiogenic shock. Beta blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and aldosterone antagonists were prescribed in 18.8%, 10.6%, and 5.0% of patients, respectively. The observed 30-day mortality among patients was higher in patients who received beta or renin-angiotensin-aldosterone system blockers prior to cardiogenic shock resolution. Compared with patients not given beta or renin-angiotensin-aldosterone system blockers, the 30-day mortality was higher among patients treated only with beta-blockers but not among those only treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The administration of beta or renin-angiotensin-aldosterone system blockers is common in North America and Europe in patients with myocardial infarction and cardiogenic shock prior to cardiogenic shock resolution. This therapeutic practice was independently associated with higher 30-day mortality.
dcterms:title
Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock
skos:prefLabel
Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock Incidence and Outcomes Associated With Early Heart Failure Pharmacotherapy in Patients with Ongoing Cardiogenic Shock
skos:notation
RIV/00216208:11120/14:43908087!RIV14-MSM-11120___
n13:predkladatel
n14:orjk%3A11120
n3:aktivita
n17:N
n3:aktivity
N
n3:cisloPeriodika
2
n3:dodaniDat
n11:2014
n3:domaciTvurceVysledku
n6:2228734
n3:druhVysledku
n15:J
n3:duvernostUdaju
n12:S
n3:entitaPredkladatele
n16:predkladatel
n3:idSjednocenehoVysledku
21112
n3:idVysledku
RIV/00216208:11120/14:43908087
n3:jazykVysledku
n18:eng
n3:klicovaSlova
myocardial infarction; cardiogenic shock; angiotensin II receptor blockers; angiotensin-converting enzyme inhibitors; aldosterone antagonists; [beta]-blockers
n3:klicoveSlovo
n4:%5Bbeta%5D-blockers n4:angiotensin-converting%20enzyme%20inhibitors n4:angiotensin%20II%20receptor%20blockers n4:myocardial%20infarction n4:cardiogenic%20shock n4:aldosterone%20antagonists
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[CF2788B6A6F2]
n3:nazevZdroje
Critical Care Medicine
n3:obor
n5:FA
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
14
n3:rokUplatneniVysledku
n11:2014
n3:svazekPeriodika
42
n3:tvurceVysledku
Widimský, Petr
n3:wos
000329863400023
s:issn
0090-3493
s:numberOfPages
8
n7:doi
10.1097/CCM.0b013e31829f6242
n19:organizacniJednotka
11120